Biotech's next growth cycle: Renewed confidence comes with c...
Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.
Newsletters and Deep Dive digital magazine
Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.
Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.
Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.
Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.
The issue isn't whether synthetic data is useful. It is what question we are asking it to answer.
Editor's Picks
Newsletters and Deep Dive
digital magazine